Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of an Engineered Single-Domain Antibody for Targeting MET in Non-Small Cell Lung Cancer

12 Mar 2024

Abstract excerpt

The Mesenchymal Epithelial Transition (MET) receptor tyrosine kinase is upregulated or mutated in 5% of non-small-cell lung cancer (NSCLC) patients and overexpressed in multiple other cancers. We sought to develop a novel single-domain camelid antibody with high affinity for MET that could be used to deliver conjugated payloads to MET expressing cancers. From a naïve camelid variable-heavy-heavy (VHH) domain...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glycosylation and Glycoproteins Research
Share to Monoclonal and Polyclonal Antibodies Research
Share to RNA and protein synthesis mechanisms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38470611
DOI: 10.1021/acs.bioconjchem.4c00019

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of an Engineered Single-Domain Antibody for Targeting MET in Non-Small Cell Lung CancerPMID 38470611Read ↗

A Biparatopic Antibody-Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade.Semantic proximity Read ↗

humMR1, a highly specific humanized single chain antibody for targeting EGFRvIII.Semantic proximity Read ↗

Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell VectorSemantic proximity Read ↗

Discovery of a novel human antibody VH domain with potent activity against mesothelin expressing cancer cells in both CAR T-cell and antibody drug conjugate formatsSemantic proximity Read ↗

Development of a MET-targeted single-chain antibody fragment as an anti-oncogene targeted therapy for breast cancerSemantic proximity Read ↗

Preclinical Evaluation of PTK7-Targeted Radionuclide TherapySemantic proximity Read ↗

Biological evaluation of new TEM1 targeting recombinant antibodies for radioimmunotherapy: In vitro, in vivo and in silico studies.Semantic proximity Read ↗

Identification and characterization of a suite of tumor targeting peptides for non-small cell lung cancer.Semantic proximity Read ↗

Identification of a novel peptide ligand for the cancer-specific receptor mutation EGFRvIII using high-throughput sequencing of phage-selected peptides.Semantic proximity Read ↗

Novel humanized monoclonal antibodies against ROR1 for cancer therapySemantic proximity Read ↗

Development of antibody-drug conjugates targeting L1CAM to treat metastatic cancerSemantic proximity Read ↗

Generation of a Synthetic Single Domain Antibody Library for Radiopharmaceutical Ligand DiscoverySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.